Iovance Biotherapeutics, Inc. IOVA Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$390.98M-5.1% | -$372.18M+16.2% | -$444.04M-12.2% | -$395.89M-15.7% | ||
| $12.68M+3.5% | $12.25M+6.4% | $11.51M+23.6% | $9.31M+199% | ||
| $61.58M-43.8% | $109.63M+75.1% | $62.63M-25.5% | $84.02M+20.4% | ||
| -$302.41M+14.3% | -$352.98M+2.4% | -$361.82M-23.6% | -$292.76M-28.4% | ||
| $33.84M+206% | $11.07M-50.3% | $22.29M+9.1% | $20.43M-45.6% | ||
| $47.5M— | —— | -$155.24M-161% | $256.46M+194,184% | ||
| $300.77M-23.0% | $390.66M-15.6% | $462.96M+143% | $190.15M-20.5% | ||
| —— | -$59.27M-4.3% | -$56.84M-137% | $153.85M— | ||
| -$336.24M+7.6% | -$364.05M+5.2% | -$384.11M-22.6% | -$313.18M-18.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Iovance Biotherapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Iovance Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.